about
Neuropsychological profile in a large group of heart transplant candidates.The SAPIEN 3 valve: lights and shadows.Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413).Comparison of balloon-expandable versus self-expandable valves for transcatheter aortic valve implantation in patients with low-gradient severe aortic stenosis and preserved left ventricular ejection fraction.Takayasu arteritis and NYHA III/IV idiopathic cardiomiopathy: tocilizumab proves effective and safe.Impact of drug-eluting stent generation on patient- and stent-related adverse events of diabetic patients treated by percutaneous coronary intervention.Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies.Left atrial appendage closure: beyond the artifact.Mechanical interference between a closure device and the rigid stent of mitral bioprosthesis: a mechanism for closure device late dislodgement.Unravelling the (arte)fact of increased pacemaker rate with the Edwards SAPIEN 3 valveMitral paravalvular leak closure by antegrade percutaneous approach: three-dimensional transesophageal echocardiographic guided multiple Amplatzer implantation by a modified sequential anchoring-based technique[New Technologies in coronary interventional cardiology: results from the first inter-regional survey promoted by SICI-GISE in four regions of northern Italy ("the GISE TOLOVE" area: Tuscany, Lombardy, Veneto, Emilia-Romagna)][The PRAMI study]The interplay between permanent pacemaker implantation and mortality in patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis
P50
Q34105183-E3B81BE6-7AEF-4E37-83C1-D28EF3E220C6Q38256798-44567CF2-4377-44F5-9ABF-46D03E8E467BQ38376848-9A10EC72-BEBC-464C-A479-5F701C4777E8Q46115757-0FFCAC42-319F-4ACD-BB9E-F732EF8BCF32Q46181044-B339F401-72FD-45D4-95C1-FA4CE36DABB2Q46772076-729BCB60-51E3-46FF-BDEB-F37713FCF1D5Q52364520-3D908BC7-1EF5-4CD0-BB71-96CCAD8CE6DAQ53060871-F49C5210-300E-4674-8C21-EA2CA1CA2C13Q53499047-DE32A6A8-EC0F-43B9-B837-8456C5749298Q86012460-805C02DA-308A-40AC-B314-59F99A534601Q86647851-5A12FA8F-E97E-4988-8839-7B5ED658A818Q86985595-BC81DB27-C500-4524-BF4F-F838BBC5BA67Q87976598-01CA0916-88DB-435B-9D5D-283F6D317E80Q90308402-3E0731A7-112C-45C8-87D3-CFFAF663A0D0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Mojoli
@ast
Marco Mojoli
@en
Marco Mojoli
@es
Marco Mojoli
@nl
type
label
Marco Mojoli
@ast
Marco Mojoli
@en
Marco Mojoli
@es
Marco Mojoli
@nl
prefLabel
Marco Mojoli
@ast
Marco Mojoli
@en
Marco Mojoli
@es
Marco Mojoli
@nl
P106
P21
P31
P496
0000-0002-6851-5946